Announcements Trials
Browse Landscape

Phase

Phase 4 3Phase 3 2Phase NA 1Phase 2 1

Status

Completed 2Enrolling by invitation 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Endocrine 3NET 1Genitourinary 1Dermatologic 1CNS 1

Conditions

Pituitary Neoplasms 3Acromegaly 2Prostatic Neoplasms 1Prolactinoma 1Prolactin Deficiency, Isolated 1Pituitary ACTH Hypersecretion 1Neuroendocrine Tumors 1Neoplasms 1Melanoma 1Hyperprolactinemia 1Dumping Syndrome 1Brain Neoplasms 1

Interventions

Dexmedetomidine 3Cabergoline 3pegvisomant 1pasireotide 1lanreotide 1Trimethoprim 1Sulfamethoxazole 1Sodium Chloride 1Sevoflurane 1Saline Solution 1Propofol 1Prednisone 1Octreotide 1Ibuprofen 1Hydrocortisone 1Hormone Replacement Therapy 1Cefdinir 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 4 × Pituitary Neoplasms × Cabergoline × Clear all
NCT07034859 2025-06-24

Cabergoline in the Management of Nonfunctioning Pituitary Adenoma

National Taiwan University Hospital

Phase 4 Enrolling by invitation
30 enrolled
Endocrine

Pituitary Neoplasms

NCT01794793 2024-10-01

Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies

RECORDATI GROUP

Phase 4 Completed
337 enrolled 8 charts
DermatologicEndocrineGenitourinaryNET

Acromegaly, Dumping Syndrome, Melanoma, Neoplasms, Pituitary Neoplasms, Prostatic Neoplasms, Neuroendocrine Tumors, Pituitary ACTH Hypersecretion

NCT00376064 2017-03-06

Efficacy of Octreotide Acetate and Cabergoline in Patients With Acromegaly

Novartis

Phase 4 Completed
20 enrolled
CNSEndocrine

Acromegaly, Brain Neoplasms, Pituitary Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡